Fatty liver disease is common among people considering these drugs, usually undiagnosed, and almost never priced. This is what it costs when somebody does get diagnosed — and what treating it is modeled to cost is a separate calculation entirely.
What was measured
A retrospective study of closed health-plan claims from 2016 to mid-2025, covering 155,172 adults aged 18 to 64 with type 2 diabetes. [1] Those with a MASLD diagnosis were propensity-matched one to one against those without, leaving 17,412 pairs, and all-cause direct healthcare costs were compared over twelve months.
Mean total costs were $29,734 with MASLD and $18,320 without — an adjusted cost ratio of 1.62, 95% CI 1.58 to 1.67, corresponding to $11,411 more per patient per year. Utilization was higher across every service setting.
Diagnosed is doing a lot of work
MASLD is largely silent. Being diagnosed with it means somebody ordered imaging or blood work and followed it up, which happens more often to people who are sicker, better insured, or already under investigation for something else.
So a matched comparison between diagnosed and undiagnosed patients is partly a comparison between people who got worked up and people who did not. Propensity matching on claims records cannot separate those, and the effect runs in the direction that inflates the cost difference.
Whose money this is
A health plan’s. Closed-claims data records what an insurer paid, not what a patient paid, and the $11,411 is spending avoided by a payer if the condition is avoided.
That is the same structure as every cost-offset finding this site has covered: real money, moving between institutions a reader is not part of. Somebody paying cash for a GLP-1 sees none of it, which is also true of the healthcare offsets measured for the drug itself.
The part a buyer can use
Not the dollar figure. The fact that fatty liver disease is expensive once it is found, and that most people who have it do not know — which makes a case for asking about it rather than for buying anything.
These drugs do improve liver measures, and one now holds a conditional approval in a staged population. But an approval attached to a fibrosis stage requires knowing your stage, and nothing in a monthly subscription establishes it. The honest accounting is that MASLD is a real cost nobody includes in the price of a GLP-1, and that it is paid by insurers, over years, for a condition most buyers have never been tested for. The six-month view covers none of that, and is not meant to.